FDA Supports Bayesian Statistics: Leap Forward or New Bias?

The FDA has issued draft guidance supporting the use of Bayesian statistical methods in confirmatory clinical trials for drugs and biologics, allowing integration of prior evidence to improve trial efficiency and reduce development costs. While some experts praise this as a significant advancement, others caution about potential biases introduced by prior distributions in Bayesian analyses.

This Wire brief sits within Fusion42's coverage of Health.